-
公开(公告)号：US20220106339A1
公开(公告)日：2022-04-07
申请号：US17432668
申请日：2020-02-21
Applicant: OBI PHARMA, INC.
Inventor： Cheng-Der Tony Yu , Yih-Huang Hsieh , Shu-Yi Lin , Chin-Sheng Chao , Yin-Cheng Hsieh , Ming-Tain Lai
IPC: C07F9/24 , C07C231/14
Abstract: A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.
-
公开(公告)号：US10766914B2
公开(公告)日：2020-09-08
申请号：US16368753
申请日：2019-03-28
Applicant: OBI PHARMA, INC.
Inventor： Jian-Xin Duan , Yeyu Cao , Xiaohong Cai , Hailong Jiao , Jing Yuan Ma , Mark Matteucci
IPC: A61K31/396 , C07F9/24 , G01N33/574
Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
-
公开(公告)号：US20180258116A1
公开(公告)日：2018-09-13
申请号：US15752854
申请日：2016-11-15
Applicant: OBI Pharma, Inc.
Inventor： Jian-Xin Duan , Yeyu Cao , Xiaohong Cai , Hailong Jiao , Jing Yuan Ma , Mark Matteucci
CPC classification number: G06F16/951 , A61P35/00 , C07B2200/07 , C07F9/564 , G01N29/022 , G01N29/222 , G01N2291/0255 , G01N2291/0256 , G01N2291/0423 , G06F3/04842 , G06F16/954 , G06F17/2235 , H03H9/02622 , H03H9/1092 , H03H9/25
Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.
-
公开(公告)号：US20180086693A1
公开(公告)日：2018-03-29
申请号：US15563481
申请日：2016-04-01
Applicant: OBI PHARMA, INC.
Inventor： Jian-Xin Duan , Yeyu Cao , Xiaohong Cai , Hailong Jiao , Jing Yuan Ma , Mark Matteucci
IPC: C07C217/58 , C07D491/22 , C07D405/12 , C07C213/02 , C07H19/06
Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
-
公开(公告)号：US09902779B2
公开(公告)日：2018-02-27
申请号：US15303132
申请日：2015-04-10
Applicant: OBI PHARMA, INC.
Inventor： Cheng-Der Tony Yu , Jiann-Shiun Lai , I-Ju Chen , Cheng-Chi Wang , Yi-Chien Tsai
IPC: A61K39/395 , C07K16/28 , C07K16/30 , C07K16/32 , G01N33/574 , C12N5/16 , C07K16/44 , A61K39/00
CPC classification number: C07K16/30 , A61K2039/505 , C07K16/3015 , C07K16/303 , C07K16/44 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/72 , C07K2317/92 , C12N5/163 , G01N33/574 , G01N2400/02 , G01N2440/38
Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
-
Patent Agency Ranking
公开(公告)号：US20170029526A1
公开(公告)日：2017-02-02
申请号：US15303132
申请日：2015-04-10
Applicant: OBI PHARMA INC.
Inventor： Cheng-Der Tony YU , Jiann-Shiu LAI , I-Ju CHEN , Cheng-Chi WANG , Yi-chien TSAI
IPC: C07K16/30
CPC classification number: C07K16/30 , A61K2039/505 , C07K16/3015 , C07K16/303 , C07K16/44 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/72 , C07K2317/92 , C12N5/163 , G01N33/574 , G01N2400/02 , G01N2440/38
Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
Abstract translation: 本发明提供了结合一种或多种碳水化合物抗原的抗体或其抗原结合部分。 本文还公开了用于在有需要的受试者中抑制癌细胞的药物组合物和方法。 药物组合物包含抗体或其抗原结合部分和至少一种药学上可接受的载体。
-
公开(公告)号：US11752204B2
公开(公告)日：2023-09-12
申请号：US16671395
申请日：2019-11-01
Applicant: OBI PHARMA, INC.
Inventor： Wei-Han Lee , Nan-Hsuan Wang , Chung-Hao Chang , Yih-Huang Hsieh , Cheng-Der Tony Yu , Cheng-Chi Wang , Yu-Hsin Lin , Yu-Chen Lin , I-Ju Chen
CPC classification number: A61K39/001169 , A61K39/39 , C07H15/24 , A61K2039/55577 , A61K2039/6037 , A61K2039/6081
Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.
-
38.发明授权公开(公告)号：US11583577B2
公开(公告)日：2023-02-21
申请号：US15495470
申请日：2017-04-24
Applicant: OBI PHARMA, INC.
Inventor： Cheng-Der Tony Yu , Youe-Kong Shue , Chen-Hsin Liang , Peiwen Yu , Chwen-Cheng Chen
IPC: A61K38/00 , A61K39/00 , A61P35/00 , G01N33/574 , A61K45/06
Abstract: The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.
-
公开(公告)号：US20230018689A1
公开(公告)日：2023-01-19
申请号：US16962992
申请日：2019-01-18
Applicant: OBI PHARMA, INC.
Inventor： I-Ming Cho , Chia-Hung Chiu , Lee-Cheng Liu
Abstract: The present invention relates to a method for producing CRM197 recombinant protein in cells. The method comprises culturing a cell comprising an expression plasmid with a polynucleotide and inducing expression of the CRM197 protein.
-
公开(公告)号：US20210396759A1
公开(公告)日：2021-12-23
申请号：US17053934
申请日：2019-05-13
Applicant: OBI PHARMA, INC.
Inventor： Cheng-Der Tony Yu , Peiwen Yu , Ming-Chen Yang , Yu-Ching Lin , Chien-Chih Ou
IPC: G01N33/574 , G01N33/50
Abstract: The present invention relates to a method for predicting human immune response to therapeutic cancer vaccine. This method includes a series of culturing procedures and a modified ELISPOT assay to detect total antibody, antigen specific antibody, and cytokine induction ability from human individual's PBMC.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.013 seconds)
